Moreover, the significant reduction of p-selectin levels between T0 and T2 (p?=?0.001) observed in TIVA patients undergoing LRP, although this group of patients was composed mainly of patients at high-risk prostate cancer (as reported in Table 1), demonstrated that general anaesthetic agents used for TIVA have a better protective effect on the platelet activation in this subgroup of patients. The gene discussed is SELP; the disease is Familial prostate cancer.